MENU
Advertisement
Show Filters
Refine by Content Type
Refine by Year
Sort By:
Choose Sites to Search:
An Interview with Roxana Mehran, MD, FSCAI, FACC, FAHA
The Program Chair of the Society for Cardiovascular Angiography and Interventions' Women in Innovations initiative provides an update on how the medical community is responding to gender disparities for women in the cardiology field and for women receiving care.
Dr. Roxana Mehran Becomes ACC President for 2026-2027
April 6, 2026—Roxana Mehran, MD, assumed the role of President of the American College of Cardiology (ACC).
Cardiovascular Care for Women
A discussion with Roxana Mehran, MD, about Women in Innovations (WIN), a worldwide group of cardiologists focused on improving the medical approach to women with cardiovascular disease and promoting the professional development of women in the field of interventional cardiology.
DAPT for DES
Deciding the optimal dual-antiplatelet therapy duration for each patient.
By Usman Baber, MD, MS, and Roxana Mehran, MD
Pharmacologic Agents for Prevention of Contrast-Induced Nephropathy
Experts provide their review of the medical options available to reduce CIN after PCI.
By Eugenia Nikolsky, MD, PhD, and Roxana Mehran, MD
Sponsored by Medtronic
Understanding the Impact of TAVR in Women With Small Aortic Annulus
Insights into the SMART trial.
By Mauro Gitto, MD; Birgit Vogel, MD; Roxana Mehran, MD; Howard C. Herrmann, MD; and Didier Tchétché, MD
Are Contemporary Femoral Approaches Comparable to Radial?
Experience and data on femoral access best practices and how they stack up against the radial approach.
By Matthew I. Tomey, MD, And Roxana Mehran, MD
Ticagrelor Compared to Clopidogrel in Low-Risk ACS Patients
May 7, 2015—Roxana Mehran, MD, presented late-breaking clinical trial results showing that the antiplatelet drug ticagrelor (Brilinta, AstraZeneca) works faster and is more effective in blocking platelet activity in low-risk patients with acute coronary syndrome (ACS) than clopidogrel.
TWILIGHT Study Supports Ticagrelor Monotherapy at 3 Months After PCI and DAPT
September 26, 2019—The Cardiovascular Research Foundation (CRF) announced that results from the TWILIGHT study were presented by investigator Roxana Mehran, MD, at TCT 2019, the 31st annual Transcatheter Cardiovascular Therapeutics scientific symposium, which is sponsored by CRF and held September 25–29 in San Francisco, California.
Shorter DAPT Regimen With Abbott's Xience V DES Is Noninferior to Standard DAPT for Ischemic Events
October 15, 2020—Results from the XIENCE 90/28 clinical trials presented by Roxana Mehran, MD, at TCT Connect have shown that a shorter course of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) was noninferior to standard DAPT up to 12 months.
Penumbra Initiates CHEETAH-ACS Trial of CAT RX Continuous Aspiration Thrombectomy Catheter
September 16, 2022— Penumbra, Inc. announced it will initiate a randomized controlled trial to evaluate thrombectomy with the company’s CAT RX continuous aspiration thrombectomy catheter plus percutaneous coronary intervention (PCI) compared to PCI alone in patients with high thrombus burden presenting with acute coronary syndrome (ACS).
Analysis of LEADERS FREE Supports Similar PCI Treatment in Women as in Men With High Bleeding Risk
May 29, 2020—The American College of Cardiology announced a recently published study that demonstrated that women with high bleeding risk should not be denied the benefits of percutaneous coronary intervention (PCI) when indicated and that bleeding avoidance strategies should be uniformly adopted for all patients, especially in women.
Abbott Supports Women as One’s CLIMB Research Initiative to Increase Diversity in Cardiology Trials
May 11, 2022—Abbott announced a new partnership with Women as One to launch CLIMB Research, a program designed to train more female and underrepresented physicians in cardiology to pursue clinical trial research and help recruit clinical trial participants from historically underrepresented groups.
Concepts in PCI
By Ted E. Feldman, MD, FESC, FACC, FSCAI
Study Presented for Osprey Medical's Avert Contrast Modulation System
May 4, 2016—The Society for Cardiovascular Angiography and Interventions (SCAI) announced the presentation of a study demonstrating that the Avert contrast modulation system (Osprey Medical Inc.) significantly reduced the volume of radiographic dye without decreasing image quality in patients who are at risk of developing acute kidney injury (AKI) after undergoing a coronary angiography or percutaneous coronary intervention (PCI).
Women Undergoing TAVR Have a Different Risk Profile and Greater Survival Rate Than Men
May 6, 2016—The Society for Cardiovascular Angiography and Interventions (SCAI) announced that data from one of the largest national registries of transcatheter aortic valve replacement (TAVR) patients show that although women are more likely to experience vascular complications in the hospital, their 1-year survival rate is more favorable than men. The analysis from the Society for Thoracic Surgeons' (STS) and American College of Cardiology’s transcatheter valve therapy registry, the STS/ACC TVT Registry, was presented as a late-breaking clinical trial at the SCAI 2016 scientific sessions in Orlando, Florida.
OrbusNeich's Combo Dual-Therapy Stent Receives CE Mark Approval
May 27, 2013—OrbusNeich (Fort Lauderdale, FL) announced CE Mark approval and the launch of the Combo dual-therapy stent for the treatment of coronary artery disease.
MedAlliance’s SELUTION4ISR Study Begins Enrollment in the United States
January 25, 2023—MedAlliance announced that the first patient in the United States has been enrolled in the SELUTION4ISR clinical trial, which is evaluating the company’s Selution SLR sirolimus drug-eluting balloon (DEB) with sustained limus release (SLR) in the treatment of in-stent restenosis (ISR).
An Interview With Mirvat Alasnag, MD, FACC, FACP, FSCAI, FRCP
Dr. Alasnag discusses her experience as a woman in interventional cardiology, the benefits of mentorship, thoughts on treatment strategies and techniques, and more.
Medtronic Survey Highlights Need for Increased Awareness Among Women of Heart Valve Disease
April 11, 2024—Medtronic recently announced findings of its comprehensive survey on women’s perceptions and knowledge of risk factors, treatment patterns, and preventive care practices related to heart valve disease.
